The trial compares Eli Lilly’s lutetium zadavotide guraxetan with Astellas’s Xtandi (enzalutamide) or Janssen’s Zytiga ...

Data from the two Phase III trials showed that once-weekly insulin efsitora induced HbA1C reductions similar to daily insulin ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

The endorsement follows Eli Lilly's announcement of successful Phase III trial results for its once-weekly insulin efsitora, which is seen as a strong competitor to Novo Nordisk (NYSE:NVO)'s icodec.

The endorsement follows Eli Lilly's announcement of successful Phase III trial results for its once-weekly insulin efsitora, which is seen as a strong competitor to Novo Nordisk (NYSE:NVO)'s icodec.

Eli Lilly's experimental next generation weight-loss drug mimics three hormones instead of just one or two and continues to ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Eli Lilly announced positive results from two Phase III trials of once-weekly insulin efsitora alfa (efsitora) compared to daily insulin degludec for type 1 and type 2 diabetes. The trials, published ...

Eli Lilly LLY announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora alfa, its once-weekly administered investigational insulin, in adults with ...

The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...